# Bioantibody

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioantibody

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.bioantibody.com.cn
- Total disclosed funding: $15M
- Latest round: Series A (Jan 12, 2023)
- Investors on record: 4

## About

Established in 2019 and based in Nanjing, China, Bioantibody is a biopharmaceutical company that focuses on in vitro diagnostic ingredients, in vitro diagnostic reagents and the early discovery of therapeutic antibody drugs.  The company has independently developed antigenic antibody materials for more than 60 diagnostic targets, with a total of more than 1200 customers as of 2023.

The company's main business is the development, production and sale of in vitro diagnostic materials and early detection of therapeutic antibodies. The company's self-developed antibody products include monkeypox ingredients, COVID-19, infectious disease, oncology indicators, cardiovascular, inflammation, kidney injury and diabetes products.

## Funding rounds

- Series A, Jan 12, 2023, $15M — Fang Fund Partners, Coastal Capital, Guoqian Venture Capital, Nanjing New Industry Investment

## Investors

- Fang Fund Partners (https://capitalatlas.ai/funds/fang-fund-partners) — Series A
- Coastal Capital (https://capitalatlas.ai/funds/coastal-capital) — Series A
- Guoqian Venture Capital (https://capitalatlas.ai/funds/guoqian-venture-capital) — Series A
- Nanjing New Industry Investment (https://capitalatlas.ai/funds/nanjing-new-industry-investment) — Series A